Codexis, Inc. (NASDAQ:CDXS) price target raised to $22.50 by HC Wainwright

ME Staff
-
0

Analyst Ratings For Codexis, Inc. (NASDAQ:CDXS)

Today, HC Wainwright raised its price target on Codexis, Inc. (NASDAQ:CDXS) to $22.50 per share.

There are 6 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Codexis, Inc. (NASDAQ:CDXS) is Buy with a consensus target price of $21.5833 per share, a potential 3.22% upside.

Some recent analyst ratings include

  • 1/17/2019-Codexis, Inc. (NASDAQ:CDXS) gets upgraded to Outperform by First Analysis with a price target of $19.00
  • 6/19/2018-Codexis, Inc. (NASDAQ:CDXS) has coverage initiated with a Outperform rating and $18.00 price target
  • On 2/26/2019 Dennis P Wolf, Director, sold 9,000 with an average share price of $21.96 per share and the total transaction amounting to $197,640.00.
  • On 2/12/2019 James Lalonde, SVP, sold 17,915 with an average share price of $21.63 per share and the total transaction amounting to $387,501.45.
  • On 1/25/2019 Gordon Sangster, CFO, sold 75,000 with an average share price of $16.94 per share and the total transaction amounting to $1,270,500.00.
  • On 12/28/2018 Thomas R Baruch, Director, sold 25,000 with an average share price of $16.03 per share and the total transaction amounting to $400,750.00.
  • On 12/27/2018 Thomas R Baruch, Director, sold 12,500 with an average share price of $16.09 per share and the total transaction amounting to $201,125.00.
  • On 12/26/2018 Dennis P Wolf, Director, sold 9,000 with an average share price of $15.83 per share and the total transaction amounting to $142,470.00.
  • On 12/20/2018 Patrick Y Yang, Director, sold 50,000 with an average share price of $18.52 per share and the total transaction amounting to $926,000.00.

About Codexis, Inc. (NASDAQ:CDXS)
Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

Recent Trading Activity for Codexis, Inc. (NASDAQ:CDXS)
Shares of Codexis, Inc. closed the previous trading session at 20,91 −0,71 3,28 % with 380700 shares trading hands.